September, 2016

EC granted € 5M to a consortium in which Blueclinical is responsible for the regulatory plan and early clinical trials

Blueclinical is part of a H2020 Consortium which is working on an innovative approach to treat Rheumatoid Arthritis. It should reach phase I clinical trials in 2018.